Butantan Institute, a biomedical research centre in Brazil, has developed a potential COVID-19 vaccine and will seek regulatory approval to begin human trials, according to two sources familiar with the matter, Reuters news agency reported on Friday,
The sources said that Butantan plans to test the vaccine, named Butanvac, on 1,800 volunteers over two phases.
This vaccine has been 100% developed in Brazil by an international consortium that also includes Vietnam and Thailand.
Production on a large scale is anticipated to start in May 2021.
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
WuXi Biologics honoured for water security by CDP
Clario acquires imaging provider NeuroRx
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services